Borealis Foods’ Owner Amplifies Warrant Stakes Amid Restructuring Hopes—Sergii Buys 2.6 Million Warrants for Just $0.07‑$0.14 Each, Betting on Plant‑Based Turnaround <|end|>

Insider Buying Swells Amid a Restructuring‑Rumored Horizon Borealis Foods Inc. (BFR) has seen a surge of warrant purchases by owner Diachenko Sergii in March and again through September 2024, with over 2.6 million warrants now held. The cumulative cost of the trades averages around $0.07–$0.14 per warrant, well below the current share price of $1.51, indicating a bullish stance on the company’s long‑term prospects. The most recent batch on 2024‑10‑08 added almost 44,000 warrants, pushing the holder’s stake to roughly 6.6 % of the total warrant class.

What the Buying Signals for Investors Sergii’s sustained buying amid a 73 % year‑to‑date decline and a negative P/E ratio suggests confidence that the company’s restructuring plans will unlock value. The influx of warrants could signal a belief that the plant‑based, ready‑to‑eat segment will rebound as consumer demand for alternative proteins steadies. For equity holders, the influx may mean potential upside if the warrants are exercised when the stock price recovers, but it also adds pressure for a price increase to justify the warrant premium. Short‑term traders may view the low activity and muted social‑media buzz as a neutral backdrop, while long‑term investors might see an opportunity to acquire exposure at a discount.

Diachenko Sergii: A Pattern of Patient Accumulation Historically, Sergii has been a patient accumulator, buying in increments ranging from a few hundred to tens of thousands of warrants. His purchases cluster around periods of market volatility and after major corporate announcements, indicating a strategy that capitalizes on pricing inefficiencies. The most significant trade, 46,403 warrants in May 2025, suggests a decisive bet during a period of corporate restructuring. The pattern of regular, sizable purchases—especially the spike on 2024‑07‑26 with 54,240 warrants—demonstrates a willingness to commit capital in anticipation of a strategic turnaround.

Implications for the Company’s Future Borealis’s focus on plant‑based products aligns with broader industry trends toward sustainable nutrition. The company’s restructuring, coupled with the influx of warrant holders, could provide the capital base needed to scale production, expand distribution, and invest in R&D. However, the current negative earnings and low liquidity raise concerns about the company’s ability to meet short‑term obligations. If the warrants are exercised en masse, it could dilute equity but also infuse fresh capital, potentially stabilizing the balance sheet.

Bottom Line for Investors Sergii’s buying spree signals confidence but does not guarantee a quick turnaround. Investors should monitor the company’s earnings reports, restructuring milestones, and any changes in the warrant terms. While the current sentiment is neutral and trading volume is subdued, the underlying long‑term growth potential in the plant‑based space may justify a watchful, long‑term hold for value‑seekers willing to ride through volatility.